H.C. Wainwright raised the firm’s price target on Tyra Biosciences to $30 from $25 and keeps a Buy rating on the shares. The firm highlights the TYRA-300 abstract at the Triple Meeting conference, taking place October 23-25 in Barcelona, Spain.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Tyra Biosciences management to meet virtually with Piper Sandler
- Tyra Biosciences price target raised to $33 from $25 at Oppenheimer
- Tyra Biosciences management to meet with Oppenheimer
- Tyra Biosciences appoints Doug Warner as Chief Medical Officer
- Brinker upgraded, Snowflake downgraded: Wall Street’s top analyst calls